Combination therapy in dyslipidemia: Where are we now?

Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec

Research output: Contribution to journalArticle

Abstract

Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0mmol/L (38.7mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%.Several lipid goal-driven guidelines recommend reducing LDL-C to

Original languageEnglish
Pages (from-to)319-335
Number of pages17
JournalAtherosclerosis
Volume237
Issue number1
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • Combination therapy
  • Ezetimibe
  • Fibrate
  • LDL-C
  • Niacin
  • PCSK9
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Combination therapy in dyslipidemia: Where are we now?'. Together they form a unique fingerprint.

  • Cite this

    Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014). Combination therapy in dyslipidemia: Where are we now? Atherosclerosis, 237(1), 319-335. https://doi.org/10.1016/j.atherosclerosis.2014.09.026